Bessemer Group Inc. Lowers Holdings in The Cooper Companies, Inc. $COO

Bessemer Group Inc. decreased its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 0.1% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,828,876 shares of the medical device company’s stock after selling 1,685 shares during the quarter. Bessemer Group Inc. owned approximately 0.91% of Cooper Companies worth $130,144,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of COO. Zions Bancorporation National Association UT purchased a new position in Cooper Companies during the first quarter worth approximately $33,000. GKV Capital Management Co. Inc. purchased a new position in Cooper Companies during the first quarter worth approximately $40,000. J.Safra Asset Management Corp boosted its position in Cooper Companies by 204.8% during the second quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company’s stock worth $36,000 after purchasing an additional 340 shares in the last quarter. Larson Financial Group LLC boosted its position in Cooper Companies by 1,071.0% during the first quarter. Larson Financial Group LLC now owns 726 shares of the medical device company’s stock worth $61,000 after purchasing an additional 664 shares in the last quarter. Finally, HM Payson & Co. boosted its position in Cooper Companies by 147.4% during the first quarter. HM Payson & Co. now owns 893 shares of the medical device company’s stock worth $75,000 after purchasing an additional 532 shares in the last quarter. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Cooper Companies Price Performance

NASDAQ:COO opened at $72.85 on Tuesday. The Cooper Companies, Inc. has a one year low of $61.78 and a one year high of $108.01. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.24 and a current ratio of 2.12. The stock has a market cap of $14.48 billion, a PE ratio of 35.89, a P/E/G ratio of 1.93 and a beta of 1.02. The stock has a 50 day moving average price of $69.66 and a 200 day moving average price of $73.18.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Wednesday, August 27th. The medical device company reported $1.10 EPS for the quarter, beating the consensus estimate of $1.07 by $0.03. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The firm had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter last year, the firm earned $0.96 earnings per share. The business’s revenue for the quarter was up 5.7% on a year-over-year basis. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. Equities research analysts expect that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies announced that its board has initiated a stock repurchase program on Wednesday, September 17th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical device company to buy up to 15.4% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on COO shares. Mizuho lowered their price target on Cooper Companies from $105.00 to $90.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 16th. BNP Paribas Exane upgraded Cooper Companies from a “neutral” rating to an “outperform” rating and set a $92.00 price target on the stock in a research report on Tuesday, July 22nd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Cooper Companies in a research report on Wednesday, October 8th. Needham & Company LLC restated a “buy” rating and issued a $94.00 target price on shares of Cooper Companies in a research report on Thursday, August 28th. Finally, Wall Street Zen downgraded Cooper Companies from a “buy” rating to a “hold” rating in a research report on Saturday, July 12th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Cooper Companies has a consensus rating of “Moderate Buy” and a consensus target price of $84.77.

Insider Transactions at Cooper Companies

In related news, Director Lawrence Erik Kurzius purchased 2,000 shares of the business’s stock in a transaction that occurred on Monday, September 29th. The stock was purchased at an average price of $68.39 per share, with a total value of $136,780.00. Following the completion of the acquisition, the director owned 5,777 shares in the company, valued at $395,089.03. This trade represents a 52.95% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Brian G. Andrews purchased 1,525 shares of the business’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was bought at an average cost of $65.68 per share, with a total value of $100,162.00. Following the acquisition, the executive vice president owned 22,191 shares of the company’s stock, valued at approximately $1,457,504.88. The trade was a 7.38% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 17,975 shares of company stock valued at $1,216,346. 1.98% of the stock is currently owned by company insiders.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.